First experiments with novel quinazolinone inhibitor ATH434 (previously known as PBT434) revealed reduced levels of α-synuclein and markers of oxidative stress accompanied by motor improvement in PD animal models [69]. The gene discussed is SNCA; the disease is Parkinson disease.